AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20694567 — intervention group
Group type: COMPARATOR
Intervention: Static seating pressure (P) with G-Cem (GC)
Number of subjects: 56
Study 20694567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration (V) with Gradia Forte (GA)
Number of subjects: 56
Study 20694567 — intervention group
Group type: COMPARATOR
Intervention: Static seating pressure (P) with Gradia Forte (GA)
Number of subjects: 56
Study 20694567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration (V) with RelyX Unicem (RUC)
Number of subjects: 56
Study 20694567 — intervention group
Group type: COMPARATOR
Intervention: Static seating pressure (P) with RelyX Unicem (RUC)
Number of subjects: 56
Study 20694567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration (V) with RelyX Unicem Aplicap (RUA)
Number of subjects: 56
Study 20694567 — intervention group
Group type: COMPARATOR
Intervention: Static seating pressure (P) with RelyX Unicem Aplicap (RUA)
Number of subjects: 56
Study 19327753 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 0
Study 19327753 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused distraction
Number of subjects: 0
Study 19327753 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 0
Study 15583076 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 15583076 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study 9973019 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol (nonionic)
Number of subjects: 2000
Study 9973019 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (ionic)
Number of subjects: 2000
Study 7749822 — intervention group
Group type: COMPARATOR
Intervention: 0 eggs added per day
Number of subjects: 13
Study 7749822 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg added per day
Number of subjects: 13
Study 7749822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 eggs added per day
Number of subjects: 13
Study 7749822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake
Number of subjects: 13
Study 2406105 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy using the patient's tumor cells to create a vaccine
Number of subjects: 0
Study 2406105 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved surgical techniques and instrumentation
Number of subjects: 0
Study 2406105 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 2406105 — intervention group
Group type: EXPERIMENTAL
Intervention: Further basic scientific and clinical research
Number of subjects: 0
Study 7413719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg daily of cannabidiol (CBD) for 30 days in healthy volunteers
Number of subjects: 31
Study 7413719 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-300 mg daily of cannabidiol (CBD) for 4 1/2 months in epilepsy patients
Number of subjects: 31
Study 7413719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose capsules) for 30 days in healthy volunteers
Number of subjects: 31
Study 7413719 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 1/2 months in epilepsy patients
Number of subjects: 31
Study 31693265 — intervention group
Group type: EXPERIMENTAL
Intervention: My Guide smartphone application
Number of subjects: 80
Study 31693265 — intervention group
Group type: EXPERIMENTAL
Intervention: My Health smartphone application
Number of subjects: 80
Study 29860242 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-reduced diets varying in macronutrient intake
Number of subjects: 504
Study 29860242 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 504
Study 27886657 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-15-minute brief negotiated interview (BNI)
Number of subjects: 528
Study 27886657 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-45-minute adaptation of motivational interviewing (MOTIV)
Number of subjects: 528
Study 27886657 — intervention group
Group type: COMPARATOR
Intervention: No brief intervention (Control)
Number of subjects: 528
Study 25966826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic BP in patients who did not experience MACE
Number of subjects: 2049
Study 25966826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic BP before MACE in those who experienced MACE
Number of subjects: 2049
Study 25966826 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile based on mean systolic BP
Number of subjects: 2049
Study 25966826 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability of systolic BP
Number of subjects: 2049
Study 25966826 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate BP control
Number of subjects: 2049
Study 24028755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of salbutamol (15 μg/kg IBW/hour)
Number of subjects: 326
Study 24028755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 326
Study 21327795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry immersion for 7 days
Number of subjects: 8
Study 21327795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after dry immersion
Number of subjects: 8
Study 21327795 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position after immersion
Number of subjects: 8
Study 19660492 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release morphine
Number of subjects: 0
Study 19660492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone plus acetaminophen
Number of subjects: 0
Study 19660492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18261269 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine maleate and bacillus licheniformis (Group A)
Number of subjects: 129
Study 18261269 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine maleate (Group B)
Number of subjects: 129
Study 18261269 — intervention group
Group type: COMPARATOR
Intervention: Bacillus licheniformis (Group C)
Number of subjects: 129
Study 18261269 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 129
Study 18261269 — intervention group
Group type: COMPARATOR
Intervention: Group A and B vs Group C
Number of subjects: 129
Study 18261269 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse drug reactions in Group A and B
Number of subjects: 129
Study 15089956 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of an oral analgesic algorithm derived from systematic reviews
Number of subjects: 4
Study 15089956 — intervention group
Group type: COMPARATOR
Intervention: Control wards (no intervention initially)
Number of subjects: 4
Study 15089956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control wards
Number of subjects: 4
Study 11791961 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat germ (WG) 2 g, 3 times a day for 10 days
Number of subjects: 63
Study 11791961 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg 3 times a day) plus WG
Number of subjects: 63
Study 11791961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch, 2 g, 3 times a day)
Number of subjects: 63
Study 11791961 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (250 mg 3 times a day) plus placebo
Number of subjects: 63
Study 9569649 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming the stereotype of professors or the trait intelligent
Number of subjects: 0
Study 9569649 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming the stereotype of soccer hooligans or the trait stupid
Number of subjects: 0
Study 9569649 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged priming
Number of subjects: 0
Study 9569649 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming effects
Number of subjects: 0
Study 8072199 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF 39-300 (10 micrograms/kg daily via intravenous infusion for 21 days)
Number of subjects: 53
Study 8072199 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF 39-300
Number of subjects: 53
Study 8072199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8072199 — intervention group
Group type: COMPARATOR
Intervention: CSF 39-300 and Placebo
Number of subjects: 53
Study 3053041 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet regimens
Number of subjects: 0
Study 3053041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28929861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate (10 mg/d)
Number of subjects: 10
Study 28929861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28281111 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch Surgery™ (TS)
Number of subjects: 105
Study 28281111 — intervention group
Group type: COMPARATOR
Intervention: Virtual Reality (VR) trainer
Number of subjects: 105
Study 26653668 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (ABT)
Number of subjects: 111
Study 26653668 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone
Number of subjects: 111
Study 26653668 — intervention group
Group type: COMPARATOR
Intervention: Control (RA control)
Number of subjects: 111
Study 26653668 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT/MTX group
Number of subjects: 111
Study 26653668 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT
Number of subjects: 111
Study 24923077 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg bevacizumab
Number of subjects: 59
Study 24923077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 59
Study 24923077 — intervention group
Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 59
Study 21919691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 or 20 mg twice daily)
Number of subjects: 0
Study 21919691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18640473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1.5 g/d (MET group)
Number of subjects: 57
Study 18640473 — intervention group
Group type: COMPARATOR
Intervention: Control group (antioxidants)
Number of subjects: 57
Study 16570434 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingjin group (acupuncture)
Number of subjects: 110
Study 16570434 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 12844280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (benzodiazepines and conventional antipsychotics)
Number of subjects: 11
Study 12844280 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (ziprasidone, risperidone, olanzapine)
Number of subjects: 11
Study 12844280 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 11
Study 12844280 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 11
Study 10475514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% sodium lauryl sulfate (SLS)
Number of subjects: 139
Study 10475514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% sodium lauryl sulfate (SLS)
Number of subjects: 139
Study 10475514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium lauryl sulfate (SLS)
Number of subjects: 139
Study 10475514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium lauryl sulfate (SLS)
Number of subjects: 139
Study 10475514 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% sodium lauryl sulfate (SLS)
Number of subjects: 139
Study 7847265 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + TS
Number of subjects: 150
Study 7847265 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 150
Study 2017017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate (LCHO) diet
Number of subjects: 7
Study 2017017 — intervention group
Group type: COMPARATOR
Intervention: Moderate carbohydrate (MCHO) diet
Number of subjects: 7
Study 2017017 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate (HCHO) diet
Number of subjects: 7
Study 7137533 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially purified timothy extract
Number of subjects: 0
Study 7137533 — intervention group
Group type: COMPARATOR
Intervention: Two timothy major allergens (Nos. 19 and 25)
Number of subjects: 0
Study 30958358 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 410
Study 30958358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DST variability
Number of subjects: 410
Study 30958358 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed in ApoE4 carriers
Number of subjects: 410
Study 28061907 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 72/9.6 μg BID
Number of subjects: 0
Study 28061907 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 36/9.6 μg BID
Number of subjects: 0
Study 28061907 — intervention group
Group type: COMPARATOR
Intervention: Monocomponent MDIs
Number of subjects: 0
Study 28061907 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 0
Study 28061907 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium DPI 18 μg once daily
Number of subjects: 0
Study 28061907 — intervention group
Group type: COMPARATOR
Intervention: FF DPI 12 μg BID
Number of subjects: 0
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed decision-making (IDM) scores based on patient responses to 10 questions about decision-making.
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at the time of decision-making
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of education
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a warning about progressing to end-stage kidney disease
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication about risks and burdens of dialysis
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Option of not starting dialysis
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of choice about starting dialysis
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling rushed to make a decision
Number of subjects: 99
Study 23901048 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of decision-making by the doctor
Number of subjects: 99
Study 21437522 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical combination of benzoyl peroxide 5% and clindamycin 1%
Number of subjects: 23
Study 21437522 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel cream
Number of subjects: 23
Study 19884606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral analysis system of psychotherapy (CBASP) and continued pharmacotherapy (MEDS)
Number of subjects: 491
Study 19884606 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief supportive psychotherapy (BSP) and continued pharmacotherapy (MEDS)
Number of subjects: 491
Study 19884606 — intervention group
Group type: COMPARATOR
Intervention: Continued optimized pharmacotherapy (MEDS) alone
Number of subjects: 491
Study 17301637 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol levels
Number of subjects: 7388
Study 17301637 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (25 g/day or more)
Number of subjects: 7388
Study 17301637 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood pressure
Number of subjects: 7388
Study 17301637 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in serum cholesterol of 1 mmol/l
Number of subjects: 7388
Study 15073097 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 6415
Study 15073097 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening with > or = 4 microg/liter
Number of subjects: 6415
Study 15073097 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection of clinically localized cancers
Number of subjects: 6415
Study 11141144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily for one week, then 20 mg once daily for 11 weeks
Number of subjects: 60
Study 11141144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification
Number of subjects: 3234
Study 11092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus metformin
Number of subjects: 3234
Study 11092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus placebo
Number of subjects: 3234
Study 9321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified PCR based assay for NAT2 genotyping
Number of subjects: 0
Study 9321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid as probe drug
Number of subjects: 0
Study 8462143 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg sublingual GTN
Number of subjects: 25
Study 8462143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8462143 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 25
Study 2947102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 70
Study 2947102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29370143 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-REPLACE (15% carbohydrate solution; 221.4 ± 59.3 g maltodextrin)
Number of subjects: 14
Study 29370143 — intervention group
Group type: COMPARATOR
Intervention: CHO-DEFICIT (non-caloric artificially-sweetened placebo solution)
Number of subjects: 14
Study 27801937 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep apnea (when APOE ɛ4 allele is absent)
Number of subjects: 7547
Study 27801937 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep apnea (when APOE ɛ4 allele is present)
Number of subjects: 7547
Study 25108305 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP2-based rapid diagnostic test (RDT)
Number of subjects: 0
Study 23254579 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/hydrochlorothiazide (n = 26)
Number of subjects: 48
Study 23254579 — intervention group
Group type: COMPARATOR
Intervention: High-dose ARB (n = 22)
Number of subjects: 48
Study 20403303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Seal (DS)
Number of subjects: 80
Study 20403303 — intervention group
Group type: COMPARATOR
Intervention: Fissurit F (FF)
Number of subjects: 80
Study 20403303 — intervention group
Group type: COMPARATOR
Intervention: Fissurit FX (FFX)
Number of subjects: 80
Study 20403303 — intervention group
Group type: COMPARATOR
Intervention: Admira Seal (AS)
Number of subjects: 80
Study 20403303 — intervention group
Group type: EXPERIMENTAL
Intervention: All sealants
Number of subjects: 80
Study 18346603 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence (blocking noise)
Number of subjects: 63
Study 18346603 — intervention group
Group type: COMPARATOR
Intervention: Noise (ambient operating room noise)
Number of subjects: 63
Study 18346603 — intervention group
Group type: COMPARATOR
Intervention: Music (patient-selected music)
Number of subjects: 63
Study 15845509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 vaccine (10^9 CFU buffered with 1.3% NaHCO3)
Number of subjects: 45
Study 15845509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrio cholerae 638 vaccine
Number of subjects: 45
Study 15845509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buffer alone)
Number of subjects: 45
Study 12218274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (940 ppm)
Number of subjects: 13
Study 12218274 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 13
Study 10355070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (2 x 160 mg)
Number of subjects: 900
Study 10355070 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine + Verapamil (3 x 160 mg + 3 x 80 mg)
Number of subjects: 900
Study 10355070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 10355070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol, Quinidine + Verapamil, Placebo
Number of subjects: 900
Study 9064391 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CEA MoAb 99mTc‐BW 431/26
Number of subjects: 143
Study 9064391 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TAG-72 MoAb 111In‐CYT‐103
Number of subjects: 143
Study 1663244 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized educational program provided by nurses to modify maternal attitudes towards feeding.
Number of subjects: 0
Study 1663244 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study 29343175 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered care model
Number of subjects: 13
Study 27719689 — intervention group
Group type: EXPERIMENTAL
Intervention: KICk‐OFF education program
Number of subjects: 0
Study 27719689 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23242378 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserving-remnant group
Number of subjects: 62
Study 23242378 — intervention group
Group type: COMPARATOR
Intervention: Removing-remnant group
Number of subjects: 62
Study 22513778 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 1492
Study 22513778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1492
Study 20022206 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative β-blockers
Number of subjects: 0
Study 18971181 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of nalmefene (2 mg)
Number of subjects: 12
Study 18971181 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intravenous doses of nalmefene (2 mg once daily for 6 days)
Number of subjects: 12
Study 16827629 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 47
Study 16827629 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 47